Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

November 29, 2021 by Alan Khadavi

JAK inhibitors for asthma, a new treatment option

JAK inhibitors for asthma are currently being studied. Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness and cough. Many of the inflammatory pathways implicated in asthma involve factors that activate the Janus Kinase (JAK). The discovery of the Janus kinases activator of transcription (STAT) signaling pathway was a breakthrough in understanding of cell growth and differentiation.

Janus Kinase inhibitors are under active investigation for immune and inflammatory diseases, and they have demonstrated clinical efficacy in diseases such as rheumatoid arthritis and eczema.

Opzelura (ruxolitinib) for Eczema

Upadacitinib for Atopic Dermatitis (Eczema)

Abrocitinib for Atopic Dermatitis by Pfizer

Substantial preclinical data suggest that inhibiting JAK will improve airway inflammation and hyperreactivity in asthma.

JAK inhibitors have the potential to bring in a new therapy of anti-inflammatory treatment in asthma.

There are currently 5 FDA compounds for clinical use that are JAK inhibitors. 2 are for hematologic disorders (ruxolitinib and fedratinib). 3 for use in inflammatory diseases (tofacitinib, baricitinib and upadicitinib). Many are in phase 2/3 studies for a variety of conditions including RA, ulcerative colitits, psoriasis and atopic dermatitis.

Current JAK inhibitors for asthma that are being studied in animal models of lung inflammation are; Tofacitinib, P6, AZD0449, Ruxolitinib, iJak-381, LAS194046, iJAK-001, Tofacitinib. They are being studied with different routes of administration as well.

An important aspect of JAK inhibitors for asthma is balancing their potential efficacy in reducing lung inflammation with safety concerns. Potential concerns are:

  • Opportunisitic and respiratory viral infections
  • Viral reactiviation
  • Malignancy and lymphoproliferative disorders
  • Decreased lymphocyte and neutrophil counts
  • Lipid profile and cardiovascular disease
  • Venous thromboembolism

Janus kinase inhibitors for asthma should be clinically useful for multiple types of asthma. An unmet need is for patients with severe asthma whose disease is poorly controlled despite using high dose inhaled steroids and it would be less expensive that biologics. Because JAK inhibitors have a completely different mechanism of action, they may be particularly effective in individuals with asthma resistant to steroids. Inhaled JAK inhibitors will be studied.

Filed Under: Asthma, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

August 4, 2022

Lentil Allergy, a common allergen on the rise

lentil allergy

July 24, 2022

Viaskin Peanut Patch Safety Results

viaskin peanut patch

July 15, 2022

Flaxseed Allergy, an emerging allergen

flaxseed allergy

July 5, 2022

Itepekimab (Anti IL-33) & Brodalumab (Anti IL-25) for Asthma

Itepekimab and Brodalumab

June 18, 2022

Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis

roflumilast tapinarof

June 9, 2022

Avocado Allergy Comes in Many Flavors

avocado allergy

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page